Flu mRNA Vaccine Services
Seasonal influenza is an acute respiratory infection caused by influenza viruses. Vaccination isthe most effectivemethod for itsprevention
The surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) serve as the primary antigenic targets for the host immune response against influenza A virus infection The WHO recommends vaccine contains the following :
2025-2026 Northern Hemisphere
Trivalent nucleic acid-based vaccines
◼ A/Wisconsin/ 67/2022 (H1N 1)pdm 09-likevirus;
◼ A/DistrictofColumbia/ 27/2023 (H3N 2)-likevirus;
◼ B/Austria/1359417/2021 (B/Victorialineage)-likevirus
B/Yamagata lineage for quadrivalent vaccine
◼ B/Phuket/ 3073/2013 (B/Yamagata lineage)-likevirus.
Trivalent nucleic acid-based vaccines
◼ A/Wisconsin/67/2022 (H1N1)pdm09 -like virus;
◼ A/District of Columbia/27/2023 (H3N2)-like virus;
◼ B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
B/Yamagata lineage for quadrivalent vaccine
◼ B/Phuket/3073/2013 (B/Yamagata lineage) -like virus.
2025 Southern Hemisphere
RNASci provides Flu HA mRNA Product and Custom Services.
mRNA Product
Flu HA mRNA (m1 ψ)
• HA antigen for WHOrecommended strains
Naked mRNA or mRNA -LNP (SM102)
Custom Services
Sequence Design & Gene
• AI-designed 5 ’UTR
• 3’ UTR from human alpha -globin
• 100-nt poly(A)
Pipelines: mRNA-based Flu Vaccine
mRNA-1010
mRNA -1010 isan mRNA vaccine developed by Moderna for the prevention seasonal flu. Moderna submitted clearance requests with regulators in the U S , Europe, Canada and Australia. Moderna is specificallyseeking approvals to market mRNA -1010 for people at least50 years of age .
Target:HA antigen, quadrivalent (WHO recommended)
Composition: HA mRNAs encapsulated in SM 102 LNP
More Clinical Pipelines
Seasonal Influenza
mRNA -1010 HA Quadrivalent BLA Submission Moderna
BNT -161 / PF07252220 HA Quadrivalent
GSK -4382276A HA Multivalent
SP0237 HA and NA Quadrivalent
CSL400 Not available Trivalent
Phase 3 Pfizer, BioNTech
Phase 2 GSK
Phase 1/2 Sanofi
Phase 1 CSL
ARCT -2138* HA and NA Quadrivalent CSL, Arcturus
JCXH -107 Quadrivalent IND Immorna (ψψψψ)
Pandemic Influenza (H5N1)
SP0289 Not available Monovalent
GSK5536522 Not available Monovalent
Phase 2 Sanofi
Phase 2 GSK
mRNA -1018 HA Monovalent Phase 1/2 Moderna
PF -07985819 Not available Monovalent
Phase 1 Pfizer, BioNTech
CSL406* Not available Monovalent Phase 1 CSL
ARCT -2304* Not available Monovalent Phase 1 Arcturus
* = self-amplifying RNA ( saRNA ) Update: Jan 2026